随着对非ST段抬高急性冠状动脉综合征病理生理机制理解的不断深入,使其治疗方式不断得到提高,临床预后不断得到改善。低分子肝素、血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂及早期再血管化治疗对高危的患者均显示出强大的临床益处,而氯吡格雷的益处似乎覆盖了所有的低、中、高危患者,直接凝血酶抑制剂的作用值得进一步探讨。危险分层策略是作出治疗决定的基础,为新治疗的选择提供了依据。 With the deepening understanding of the pathophysiological mechanisms of non-ST segment elevation acute coronary syndromes, their treatment has been continuously improved, and their clinical prognosis has been continuously improved. Low molecular weight heparin, platelet glycoprotein IIb / IIIa receptor antagonists and early revascularization have shown strong clinical benefit in high-risk patients, and the benefit of clopidogrel appears to cover all patients with low, medium and high risk , The role of direct thrombin inhibitors worth further study. The risk stratification strategy is the basis for making treatment decisions and provides a basis for the choice of new treatment.